Name: MC-Alkyl-Hydrazine Modified MMAF
Brand: BOC Sciences
Rating: 5 (1 reviews)

Synonyms

N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]hydrazino}-4-oxobutyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(2S)-3-(1H-indol-3-yl)-1-(1,2-oxazinan-2-yl)-1-oxopropan-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide; N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]hydrazino}-4-oxobutyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(2S)-3-(1H-indol-3-yl)-1-{1,2-oxazinan-2-yl)-1-oxopropan-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide

IUPAC Name

(2S)-2-[[(2S)-2-[[4-[2-[6-(2,5-dioxopyrrol-1-yl)hexanoyl]hydrazinyl]-4-oxobutyl]-methylamino]-3-methylbutanoyl]amino]-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(2S)-3-(1H-indol-3-yl)-1-(oxazinan-2-yl)-1-oxopropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N,3-dimethylbutanamide

Canonical SMILES

O=C(N1CCCCO1)[C@@H](NC([C@H](C)[C@H]([C@@]2([H])N(CCC2)C(C[C@@H](OC)[C@@]([C@@H](C)CC)([H])N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)CCCC(NNC(CCCCCN3C(C=CC3=O)=O)=O)=O)=O)=O)=O)OC)=O)CC4=CNC5=CC=CC=C45

InChI

InChI=1S/C59H92N10O12/c1-12-39(6)54(66(9)59(78)52(37(2)3)62-57(76)53(38(4)5)65(8)29-21-26-48(71)64-63-47(70)25-14-13-17-30-68-49(72)27-28-50(68)73)46(79-10)35-51(74)67-31-20-24-45(67)55(80-11)40(7)56(75)61-44(58(77)69-32-18-19-33-81-69)34-41-36-60-43-23-16-15-22-42(41)43/h15-16,22-23,27-28,36-40,44-46,52-55,60H,12-14,17-21,24-26,29-35H2,1-11H3,(H,61,75)(H,62,76)(H,63,70)(H,64,71)/t39-,40+,44-,45-,46+,52-,53-,54-,55+/m0/s1

Shipping

Room temperature

1.Antibody drug conjugates (ADC) Current status and mapping of ADC:s in clinical programs.

Samantha Congreve, Reham Faris Elias, Gabriel Tidestav, Venus Zafrianian

A literature study was performed on a new type of cancer medicine:antibody drug conjugates, or ADCs. These consist of a monoclonalantibody, chemically linked to a cytotoxic agent. What makes themunique is their selective toxicity against cancer cells. The firstapproval of such a pharmaceutical was in the year 2000, with three orfour available in different regions of the world today. In the rangeof 50 registered drugs in clinical development were found, by majorand minor corporations. These have been presented in a table in theappendix according to their properties such as type of linker,cytotoxin, development status etc. Furthermore, a detailed study hasbeen done of the chemistry of the linker conjugation as well as anattempt at studying the ADC market. Finally, the mentioned strengthsof the drug were compared to its weaknesses, mainly instability andotherwise poor pharmacokinetics. The main conclusion is that thesedrugs are expected to play a major role in oncology in the future.

Catalog	Product Name	CAS
BADC-01432	Cys-MC-MMAF	1160590-05-5
BADC-01455	Modified MMAF-C5-COOH	1404071-65-3
BADC-00594	PEG4-aminooxy-MMAF	1415246-35-3
BADC-00320	MMAF Hydrochloride	1415246-68-2
BADC-00617	MMAF sodium	1799706-65-2
BADC-01460	DBM-MMAF	1810001-93-4
BADC-00863	DBCO-PEG4-Val-Cit-PAB-MMAF	2244602-23-9
BADC-00751	DBCO-PEG4-MMAF	2360411-65-8
BADC-00318	MMAF	745017-94-1
BADC-00694	MMAF-OMe	863971-12-4